| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/11/2002 | EP1237919A1 Interferon-alpha induced gene |
| 09/11/2002 | EP1237916A2 Ing2, an iaps associated cell cycle protein, compositions and methods of use |
| 09/11/2002 | EP1237915A2 Polynucleotid encoding the rg1 polypeptide |
| 09/11/2002 | EP1237913A2 Antigen preparations |
| 09/11/2002 | EP1237912A2 Five-helix protein |
| 09/11/2002 | EP1237911A2 Inhibition of hrsv membrane fusion |
| 09/11/2002 | EP1237909A2 Human g protein-coupled receptors |
| 09/11/2002 | EP1237582A2 Methods for introducing genes into mammalian subjects |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237574A2 Antigen delivery |
| 09/11/2002 | EP1237573A1 Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory iga's |
| 09/11/2002 | EP1237572A2 Safe attenuated bovine viral diarrhea viruses for use in pregnant cows |
| 09/11/2002 | EP1237571A2 Toscana virus nucleoprotein |
| 09/11/2002 | EP1237570A2 Fragments and antagonists of heat shock protein 60 |
| 09/11/2002 | EP1237565A1 Betaglycan as an inhibin receptor and uses thereof |
| 09/11/2002 | EP1237564A1 Inducing cellular immune responses to p53 using peptide and nucleic acid compositions |
| 09/11/2002 | EP1237558A1 Novel helicobacter pylori-binding substances and use thereof |
| 09/11/2002 | EP1237408A2 Pour-on formulations |
| 09/11/2002 | EP0769942B1 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug |
| 09/11/2002 | EP0762870B1 Virosome-mediated intracellular delivery of therapeutic agents |
| 09/11/2002 | CN1369015A Recombinant anti-CD 40 antibody and uses thereof |
| 09/11/2002 | CN1369011A Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| 09/11/2002 | CN1368885A Compositions and methods for identifying antigens which elicit an immune response |
| 09/11/2002 | CN1368506A Plasmodium fused antigen and its preparing process and usage |
| 09/11/2002 | CN1368384A Genetically engineered vaccine of MUC-1 antigen for human breast cancer |
| 09/11/2002 | CN1090676C Expression systems utilizing autolyzing fusion proteins and novel reducing polypeptide |
| 09/10/2002 | US6448389 Human cytomegalovirus DNA constructs and uses therefor |
| 09/10/2002 | US6448386 High molecular weight major outer membrane protein of moraxella |
| 09/10/2002 | US6448379 Inhibitors to il8 receptor binding, including antibodies, that interact with the amino-terminal extracellular domain of the il8 receptor and compete with il8 and other related natural ligands, for receptor-binding. |
| 09/10/2002 | US6448376 Two new proteins which appear to be new members of the e2f gene family, called e2f-5 |
| 09/10/2002 | US6448234 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 09/10/2002 | US6448223 Antagonists of HMG1 for treating inflammatory conditions |
| 09/10/2002 | US6448221 By administering an adipocyte complement related protein to reduce platelet aggregation |
| 09/10/2002 | US6448093 Solubilization of hyaluronic acid in aqueous solution of electrolyte and acid; solubilization of polar substancec (i.e. a plasmid) in mixture; acidification; dialyzing said mixture to reduce an ionic concentration past point of collapse |
| 09/10/2002 | US6448078 Inhibiting human vpr interacting protein activity in a cell using a nucletide sequence complementary to a portion of the nucleotide sequence that encodes hvip; anticancer agent |
| 09/10/2002 | US6448074 Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
| 09/10/2002 | US6448073 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| 09/10/2002 | US6448071 Effective competitors to t cell receptors and mhc molecules normally involved in transplant rejection and autoimmune disease |
| 09/10/2002 | US6448070 Recombinant plant viruses, especially their use as immunizing agents which carry antigenic sequences from mammalian or other animal pathogens and their use as a system for increased production of polypeptides of interest |
| 09/10/2002 | US6448054 Locally administering to a specific site a fugetactic agent in an amount effective to repel immune cells |
| 09/10/2002 | US6448043 Enterococcus faecalis EF040 and uses therefor |
| 09/10/2002 | US6448042 These enzymes have been implicated in a variety of disease processes, including tumor cell invasion, tumor angiogenesis and rheumatoid arthritis |
| 09/10/2002 | US6448037 PgsA |
| 09/10/2002 | US6448036 ribB |
| 09/10/2002 | US6448035 Disorders mediated by disease states associated with suppressed immune function can be treated by administering a soluble form of the negative signaling lir |
| 09/10/2002 | US6448021 Cc-chemokine receptor 2 (ccr2) bound by an antibody or functional fragment to block binding of a ligand |
| 09/10/2002 | US6448011 Isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant adrenergic receptor genes. |
| 09/10/2002 | US6448006 Methods and compositions for reducing bacterial tolerance to antibacterials disinfectants and organic solvents |
| 09/10/2002 | US6448000 Viral growth and cellular genes that function as tumor suppressors. thus, the present invention provides nucleic acids related to and methods of reducing or preventing viral infection or cancer. the invention also provides methods of |
| 09/10/2002 | US6447993 Protecting cats from infection by a broad range of fiv strains using a multi-subtype fiv vaccine. multi-subtype fiv vaccines comprising either cell free whole virus or cell lines infected with viruses and vaccinating cats |
| 09/10/2002 | US6447796 Sustained release hydrophobic bioactive PLGA microspheres |
| 09/10/2002 | US6447786 Cyclic oligopeptides used as controllers of rna transcription factors in staphylococcus grampositive bacteria; prevention of infections |
| 09/10/2002 | US6447784 Genetically engineered salmonella for use in the treatment of cancer |
| 09/10/2002 | US6447783 Compositions comprising FGF9 and use thereof for stimulating cartilage and bone repair |
| 09/10/2002 | US6447781 Administering protein complexes including antigens to humans for prevention of adenocarcinomas, melanomas, neuroblastomas, leukemia, lymphomas and mylomas; immunology; vaccines |
| 09/10/2002 | US6447780 Administering heat shock proteins (hsp) complexed with antigens; antigrowth agents or development inhibitors for cancer; immunology; vaccines |
| 09/10/2002 | US6447779 Vaccines comprising polypeptides having antigens and dna sequence codes; antiidiotypic antibodies |
| 09/10/2002 | US6447778 Peptide compositions for the treatment of HIV infection |
| 09/10/2002 | US6447776 Monoclonal antibodies against mutant amino acid sequences generated by genetic deletions or point mutations; detection of cancer |
| 09/10/2002 | US6447773 Member of ATP dependent protease family, clpL |
| 09/10/2002 | US6447769 Modified tumor cells to inhibit transforming growth factor |
| 09/10/2002 | US6447767 Delay or prevent tumor growth |
| 09/10/2002 | US6447765 Use of cytokines and mitogens to inhibit graft versus host disease |
| 09/10/2002 | CA2128247C Vaccines based on streptokinase |
| 09/06/2002 | WO2002069369A2 Cpg-like nucleic acids and methods of use thereof |
| 09/06/2002 | WO2002069198A2 Hla ligand database utilizing predictive algorithms and methods of making and using same |
| 09/06/2002 | WO2002068654A2 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus |
| 09/06/2002 | WO2002068653A2 Tri-hybrid melanoma antigen |
| 09/06/2002 | WO2002068651A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 09/06/2002 | WO2002068632A2 Methods to identify mutant cells with altered sialic acid |
| 09/06/2002 | WO2002068617A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/06/2002 | WO2002068614A2 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
| 09/06/2002 | WO2002068602A2 Methods for modulating g2a receptor activity |
| 09/06/2002 | WO2002068476A2 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 09/06/2002 | WO2002068474A1 Vaccine against cancer diseases that are associated with the her-2/neu oncogene |
| 09/06/2002 | WO2002068470A2 Interferon-alpha induced gene |
| 09/06/2002 | WO2002068457A2 Antiangiogenic peptides derived from endostatin |
| 09/06/2002 | WO2002068451A2 Sperm protein 17 for the diagnosis and treatment of cancer |
| 09/06/2002 | WO2002068444A1 Ttk in diagnosis and as a therapeutic target in cancer |
| 09/06/2002 | WO2002067990A1 Polynucleotide formulation for enhanced intracellular transfer |
| 09/06/2002 | WO2002067985A1 Method for prophylaxis and treatment of porcine reproductive and respiratory syndrome |
| 09/06/2002 | WO2002067984A2 Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection |
| 09/06/2002 | WO2002067983A1 Novel vaccine |
| 09/06/2002 | WO2002067982A2 Mycobacterial vaccines |
| 09/06/2002 | WO2002067899A1 Injectable water-in-oil emulsions |
| 09/06/2002 | WO2002067863A2 Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions |
| 09/06/2002 | WO2002067862A2 Regulation of the ctl response by macrophage migration inhibitory factor |
| 09/06/2002 | WO2002067848A2 PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE |
| 09/06/2002 | WO2002067846A2 A vaccine composition and method of using the same |
| 09/06/2002 | WO2002067760A2 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 09/06/2002 | WO2002067681A1 Restore cancer-suppressing functions to neoplastic cells through dna hypomethylation |
| 09/06/2002 | WO2002053092A3 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| 09/06/2002 | WO2002050262A3 Mutant mycobacteria for use in therapy |
| 09/06/2002 | WO2002040517A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002040049A3 Blockade of t cell migration into epithelial gvhd target tissues |
| 09/06/2002 | WO2002040037A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002039121A3 Methods for detecting the efficacy of anticancer treatments |
| 09/06/2002 | WO2002036792A3 Dna expression vectors |
| 09/06/2002 | WO2002036771A3 Imaging, diagnosis and treatment of disease |
| 09/06/2002 | WO2002024149A3 Immunogen comprising ligand bound hiv envelpe protein |